Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment
Sonia Santander Ballestín1, María Abadía Labena2, Ana Avedillo-Salas3
1Department of Pharmacology, Phisiology, and Legal-Forensic Medicine, Faculty of Health and Sports Sciences, University of Zaragoza, 22001 Huesca, Spain.
Cancers
|March 13, 2025
Summary
Adding cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to endocrine therapy significantly improves outcomes for advanced HER2-negative breast cancer. This novel treatment offers better survival and fewer chemotherapy-free intervals with lower toxicity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer is a leading cause of cancer death in women globally.
- Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors target cell cycle progression.
- These inhibitors are a novel adjuvant therapy for advanced or metastatic HER2-negative, hormone receptor-positive breast cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of CDK4/6 inhibitors combined with standard endocrine therapy.
- To analyze recent literature on CDK4/6 inhibitors in breast cancer treatment.
Main Methods:
- Systematic review of scientific literature.
- Analysis focused on studies published within the last five years.
- Evaluation of progression-free survival, overall survival, and chemotherapy-free intervals.
Main Results:
- Combination therapy significantly improved progression-free survival (PFS).
- Overall survival and chemotherapy-free intervals were also enhanced.
- CDK4/6 inhibitors demonstrated lower toxicity compared to chemotherapy.
Conclusions:
- CDK4/6 inhibitors plus endocrine therapy are a new standard for advanced HER2-negative breast cancer.
- This combination offers improved survival benefits over hormonal therapy alone.
- Further research is needed to understand and overcome treatment resistance mechanisms.
Related Concept Videos
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
02:39Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K